Advanced Glycation End Products and Oxidative Stress Are Increased in Chronic Allograft Nephropathy

American Journal of Kidney Diseases

Volumn 43, Issue 1, 2004, Pages 154-160

  Raj, Dominic S C ^a   Lim, Gideon ^b   Levi, Moshe ^b   Qualls, Clifford ^b   Jain, Sushil K ^b  

^a Division of Nephrology   (United States)

^b NONE

Author keywords

Argpyrimidine; Carbonyl protein; Carbonyl stress; Chronic allograft nephropathy (CAN); Kidney transplantation; Malonyldialdehyde; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGPYRIMIDINE; BIOLOGICAL MARKER; CARBONYL PROTEIN; CREATININE; MALONALDEHYDE; PENTOSIDINE; PROTEIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 0346098341     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.09.021     Document Type: Article

References (35)

1. Paul LC: Chronic allograft nephropathy: An update. Kidney Int 56:783-793, 1999
2. Racusen LC, Solez K, Colvin RB, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713-723, 1999
3. Cristol JP, Vela C, Maggi MF, Descomps B, Mourad G: Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplant 65:1322-1328, 1998
4. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int 41:1161-1169, 1992
5. Kees-Folts D, Diamond JR: Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol 13:365-375, 1993
6. Mene P, Pascale C, Teti A, Bernardini S, Cinotti GA, Pugliese F: Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. J Am Soc Nephrol 10:1478-1486, 1999
7. Monaco AP, Burke JF Jr, Ferguson RM, et al: Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 33:150-160, 1999
8. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
9. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101:527-537, 1984
10. Jain SK, Mc Vie R, Duett J, Herbst JJ: Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38:1539-1543, 1989
11. Jain AK, Lim G, Langford M, Jain SK: Effect of high glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N acetylcysteine: Its possible relevance to cataract formation in diabetes. Free Radic Biol Med 33:1615-1621, 2002
12. Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G: Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 10: 2110-2113, 1995
13. Padayatti PS, Ng AS, Uchida K, Glomb MA, Nagaraj RH: Argpyrimidine, a blue fluorophore in human lens proteins: High levels in brunescent cataractous lenses. Invest Ophthalmol Vis Sci 42:1299-1304, 2001
14. Stadtman ER: Protein oxidation and aging. Science 257:1220-1224, 1992
15. Odetti P, Garibaldi S, Gurreri G, et al: Protein oxidation in hemodialysis and kidney transplantation. Metabolism 45:1319-1322, 1996
16. Ishiyama A, Atarashi K, Minami M, et al: Role of free radicals in the pathogenesis of lipid-induced glomerulosclerosis in rats. Kidney Int 55:1348-1358, 1999
17. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney Int 43:1243-1250, 1993
18. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS: Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplant 58:663-669, 1994
19. Juskowa J, Paczek L, Baranska E, et al: Lipid peroxidation in renal allograft recipients. Transplant Proc 28:3474-3476, 1996
20. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
21. Miyata T, Ueda Y, Yamada Y, et al: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
22. Miyata T, Ueda Y, Yamada Y, et al: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
23. Miyata T, Ueda Y. Shinzato T, et al: Accumulation of albumin linked and free form pentosidine in th ecirculation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1997
24. Miyata T, Ueda Y, Horie K, et al: Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 53:416-422, 1998
25. Sebekova K, Podracka L, Heidland A, Schinzel R: Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation-are they interrelated? Clin Nephrol 56:S21-S266, 2001
26. Makita Z, Bucala R, Rayfield EJ, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
27. Hricik DE, Schulak JA, Sell DR, Fogarty JF, Monnier VM: Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 43:398-403, 1993
28. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD: Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 10:103-107, 1995
29. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
30. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
31. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of ldl and modified ldl with mesangial cells and matrix, Kidney Int 41:1161-1169, 1992
32. Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 45:475-484, 1994
33. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436-9440, 1994
34. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW: Products of autoxidation of both carbohydrates and lipids are increased in uremic plasma: Evidence for a generalized increase in oxidative stress in uremia. Kidney Int 54:1290-1295, 1998
35. Yan SD, Schmidt AM, Anderson GM, et al: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994